T cells are positioned at the frontline of the body’s immune system to fight infection, cancer, and autoimmune disease. While different subtypes of T cells exist, how these cells take their different forms has remained elusive.
A research team has elucidated the mechanism behind bacterial cancer therapy using a genetically engineered bacterial strain. Their findings were published in Cell.
A new article in the journal Nucleic Acid Therapeutics addresses the recognition by the U.S. Food and Drug Administration that immunogenicity assays may be necessary to measure immune responses to different components of oligonucleotide therapeutic (O…
Spring brings warmer weather, but for allergy sufferers, it also means sneezing, wheezing and itchy eyes. Instead of enjoying the season, you may be battling congestion and brain fog. So, what can you do to manage your spring allergy symptoms?
A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very small amounts of common food allergens.
Your immune system harbors a lifetime’s worth of information about threats it’s encountered—a biological Rolodex of baddies. Often the perpetrators are viruses and bacteria you’ve conquered; others are undercover agents like vaccines given to trigger p…
Dana-Farber investigators found that normally defunct viral genes that lie dormant in the human genome can be activated in the most common form of kidney cancer (clear cell renal cell carcinoma) and can end up triggering an immune response against the …
The lab of Filippo Veglia, Ph.D., at The Wistar Institute has discovered a previously unknown mechanism for how aggressive brain cancers reprogram immune system cells from fighting cancer to enabling further tumor growth. The team’s findings were publi…
An experimental treatment for an aggressive and lethal brain cancer has been published in Nature Medicine, paving the way for a clinical trial to be conducted by researchers at The Brain Cancer Center.
A comprehensive study of effective responses as well as resistant responses to a kidney cancer anti-PD-1 therapy found specific immune features that could provide new targets to improve cancer treatment, say findings published in Cancer Discovery.
